Pulse Biosciences, Inc. (PLSE) Research

Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target cells without thermal damage, effectively safeguarding adjacent non-cellular tissue. The CellFX System is applied in the treatment of various medical conditions. The company, originally incorporated in 2014 as Electroblate, Inc., officially became Pulse Biosciences, Inc. in December 2015. Its corporate headquarters are situated in Hayward, California.

Market snapshot

Symbol
PLSE
Price
$25.60
Day change
+0.59%
Market cap
$1.8B
P/E ratio
-23.27x
52-week range
12.56-28.53
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Next earnings
in 2 months
Analyst price target
$30.67

Peer companies

  • Atai Beckley Inc. (ATAI)
  • Beta Bionics, Inc. (BBNX)
  • Dianthus Therapeutics, Inc. (DNTH)
  • Immatics N.V. (IMTX)
  • Kestra Medical Technologies, Ltd. (KMTS)
  • LifeMD, Inc. (LFMD)
  • Nektar Therapeutics (NKTR)
  • NovoCure Limited (NVCR)

Recent insider activity

  • Zanganeh Mahkam — A-Award (30000 shares) on 2026-06-11
  • Zanganeh Mahkam — A-Award (14504 shares) on 2026-06-11
  • van den Broek Richard — A-Award (30000 shares) on 2026-06-11
  • van den Broek Richard — A-Award (8423 shares) on 2026-06-11
  • DUGGAN ROBERT W — A-Award (30000 shares) on 2026-06-11

Open Pulse Biosciences, Inc. (PLSE) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.